0
Inquiry Basket

There is no product in the shopping cart, buy it!

Anti-Bacterial Glycan Antibody Development Services

Overview

Bacterial surface glycans such as capsular polysaccharides (CPS), lipopolysaccharide (LPS) O-antigens, teichoic acids, and biofilm exopolysaccharides are essential for bacterial virulence and immune evasion. Antibodies directed against these glycans play crucial roles in diagnostics, vaccines, and therapeutics. Recent studies emphasize capsule–O-antigen interplay, glycan diversity, and the need for structure-defined immunogens, highlighting the importance of custom antibody solutions for translational success.

Anti-bacterial glycan antibody development services at Creative Biolabs help you generate highly specific, reliable antibodies by leveraging advanced glycoengineering, immunogen design, and multi-platform validation technologies.

We employ comprehensive strategies to design, validate, and optimize antibodies that precisely target bacterial glycans for the study of their therapeutic and diagnostic applications.

  • Authentic Immunogen Design

Chemoenzymatic synthesis and bioconjugation ensure glycans accurately replicate native bacterial epitopes.

  • Capsule and O-Antigen Awareness

Immunogen development accounts for capsule masking effects to preserve O-antigen accessibility.

  • Cross-Reactivity Control

Broad glycan arrays and competitive binding panels exclude host-like epitopes and related bacterial glycans.

  • Mechanism-Focused Screening

Selection emphasizes opsonophagocytic killing, complement deposition, or toxin neutralization to link binding with protective effect.

  • Variant and Strain Adaptability

Analytics track structural differences across strains, guiding antibody selection with robust serotype coverage.

Creative Biolabs provides antibodies that directly address the complexity of bacterial glycans. Clients receive candidates designed to overcome capsule shielding, validated against broad glycan libraries, and tested for bactericidal function. This enables reliable reagents for vaccine development, therapeutic exploration, and diagnostic assay design, ensuring that results are robust and translatable.

Learn How We Can Accelerate Your Research – Request a Consultation Today.

Service Portfolio

Anti-α/β GlcNAc-modified WTA Antibody Development

Generation of antibodies against wall teichoic acids modified with α/β-linked N-acetylglucosamine, enabling the study of bacterial adhesion, immune evasion, and Gram-positive pathogenesis.

Anti-Bacterial LPS Antibody Development

Custom development of antibodies targeting lipopolysaccharide structures in Gram-negative bacteria, supporting vaccine design, diagnostics, and septicemia research.

Anti-PNAG Antibody Development

Production of antibodies against poly-N-acetylglucosamine (PNAG) facilitating research on biofilm formation, immune protection, and antibacterial therapeutic strategies.

Anti-Psl Antibody Development

Antibody generation targeting Pseudomonas aeruginosa Psl exopolysaccharide, supporting studies of biofilm architecture, persistence, and infection control.

Anti-Alginate Antibody Development

Development of antibodies directed at alginate polysaccharides, crucial for analyzing biofilm resilience and chronic infections such as those in cystic fibrosis.

Anti-LAM/AM Antibody Development

Custom antibodies against lipoarabinomannan and arabinomannan, enabling investigations into mycobacterial cell walls, immune modulation, and tuberculosis diagnostics.

Anti-LOS Antibody Development

Antibody production targeting lipooligosaccharides of Gram-negative bacteria, supporting research in pathogenicity, vaccine candidates, and diagnostic assay design.

What We Can Offer

Custom Antibody Development

Monoclonal, recombinant, or humanized antibodies designed to target CPS, LPS, teichoic acids, or exopolysaccharides.

Glycoconjugate Preparation

Defined bacterial polysaccharides conjugated to carriers such as proteins or nanoparticles with full structural QC.

Multi-Platform Validation

Antibodies tested by glycan microarrays, ELISA, SPR/BLI, and bactericidal assays for proven reliability.

Workflow

01Immunogen Production

Generate defined glycans or glycoconjugates using chemoenzymatic synthesis and verify through MS, HPLC, or NMR.

02Antibody Generation

Use hybridoma or phage display platforms to produce diverse candidates against authentic bacterial glycans.

03Screening and Mapping

Validate specificity with glycan arrays, ELISA, and SPR, testing against host and bacterial glycans to exclude off-target activity.

04Functional Testing

Confirm activity in opsonophagocytic killing, complement deposition, and bactericidal assays, including capsule-presenting strains.

05Optimization

Improve antibody properties with affinity maturation, isotype engineering, or Fc-optimization to meet project-specific goals.

06Characterization

Deliver a full profile covering specificity, kinetics, cross-reactivity, and stability for downstream integration.

Required Starting Materials

  • Target strain or serotype information (e.g., K. pneumoniae O1v1 or S. pneumoniae CPS type).
  • Reference materials such as purified bacterial polysaccharides, clinical isolates, or comparator antibodies.

Highlights


Capsule-Informed Targeting
Approaches designed to address capsule masking and preserve effective recognition of O-antigens.

Broad Glycan Screening
Comprehensive glycan array testing to ensure specificity and minimize unexpected cross-reactivity.

Function-Linked Development
Focus on antibodies with confirmed bactericidal mechanisms, not just binding affinity.

Discover the Creative Biolabs Advantage – Contact Us for a Customized Quote.

Publication

Biofilm formation is a key survival mechanism for pathogenic bacteria, providing protection against immune defenses and antibiotics. Glycans are central to maintaining the structural integrity of the extracellular matrix. Targeting glycan-mediated pathways has emerged as a promising way to disrupt biofilm development. Structural insights into biofilm inhibitors reveal how small molecules and glycan analogs interfere with biosynthesis, destabilizing the matrix and reducing resistance. These approaches highlight new opportunities for selective antibacterial strategies that weaken harmful biofilms while sparing beneficial microbiota, offering a valuable complement to conventional antibiotics.

Fig.1 Architectures of agents targeting biofilm formation. (OA Literature)Fig.1 Configurations of biofilm-blocking compounds.1

Customer Reviews

Strain coverage
“Using Creative Biolabs’ Anti-Bacterial Glycan Antibody Development Services in our research has significantly improved opsonophagocytic killing across resistant Klebsiella isolates.” [Dr. P***]

Improved diagnostics
“Using Creative Biolabs’ Anti-Bacterial Glycan Antibody Development Services in our research has significantly stabilized our ELISA performance by minimizing cross-reactivity.” [Dr. L***]

Reliable functional data
“Using Creative Biolabs’ Anti-Bacterial Glycan Antibody Development Services in our research has significantly advanced our vaccine program with reproducible bactericidal activity.” [Dr. C***]

FAQs

Which bacterial glycans can be targeted?

We can generate antibodies against capsular polysaccharides, LPS O-antigens, teichoic acids, and exopolysaccharides from a wide range of bacteria.

How do you address cross-reactivity with host glycans?

Broad glycan arrays and competition assays ensure antibodies specifically recognize bacterial targets without binding host glycans.

Can the antibodies work across different bacterial strains?

Yes, we account for serotype variability by designing immunogens and screening strategies to maximize cross-strain coverage.

Do you confirm bactericidal activity?

Absolutely, all candidates undergo opsonophagocytic killing, complement deposition, or other functional assays depending on project needs.

Are antibodies suitable for diagnostics as well as therapeutics?

Yes, our services provide flexibility to generate antibodies validated for both research and diagnostic assay integration.

Extended Services

Glyco-based Vaccine Development Service

This service focuses on the rational design and development of vaccines using defined glycan antigens or glycoconjugates, enabling the induction of targeted and durable immune responses against pathogens or tumor-associated glycans.

High-throughput Glycan Screening Service

We provide large-scale glycan microarray and binding assays to rapidly profile antibody–glycan interactions, identify specific epitopes, and guide therapeutic or diagnostic development with precision.

Creative Biolabs’ anti-bacterial glycan antibody development services offer end-to-end solutions from immunogen design to fully validated antibodies, enabling breakthroughs in therapeutics, vaccines, and diagnostics. Contact Our Team to take the next step toward advancing your bacterial glycan research.

Reference

  1. Yakovlieva, Liubov et al. “Opportunities and Challenges of Bacterial Glycosylation for the Development of Novel Antibacterial Strategies.” Frontiers in microbiology vol. 12 745702. 24 Sep. 2021. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fmicb.2021.745702
For Research Use Only.

Related Services

Online Inquiry
Creative Biolabs-Glycoprotein Contact Us Follow us on
  • ()
    ()
    ()
ISO 9001 Certified - Creative Biolabs Quality Management System.
Close
Thanksgiving
Thanksgiving